Search

Search Constraints

You searched for: Author/Creator Brenner, A.

Search Results

1. 27LBA Evidence of activity of a new mechanism of action (MoA): A first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640, as monotherapy or in combination. Issue 3 (September 2015)

2. 2901 Phase 2 study of VB-, an anti-cancer gene therapy, as monotherapy followed by combination of VB-111 with bevacizumab, in patients with recurrent glioblastoma. (September 2015)

6. MDNA55, a Locally Administered IL4 Guided Toxin for Targeted Treatment of Recurrent Glioblastoma Shows Long Term Survival Benefit. (October 2020)